3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
CNS
1
Conditions
Melanoma
6
Lung Neoplasms
6
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Head and Neck Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Glioblastoma
3
Breast Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Sarcoma
2
Neoplasm Metastasis
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Renal Cell
2
Waldenstrom Macroglobulinemia
1
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Ureteral Neoplasms
1
Tongue Neoplasms
1
Thyroid Neoplasms
1
Interventions
Temozolomide
93
Radiotherapy
66
Bevacizumab
35
Radiation
22
Carmustine
21
Erlotinib Hydrochloride
17
Chemotherapy, Adjuvant
17
Irinotecan
16
Magnetic Resonance Spectroscopy
13
Radiotherapy, Conformal
11
O(6)-benzylguanine
11
Surgical Procedures, Operative
10
Radiotherapy, Intensity-Modulated
10
sargramostim
9
Sirolimus
9
Imatinib Mesylate
9
Carboplatin
9
temsirolimus
8
motexafin gadolinium
7
Thalidomide
7
Gene Expression Profiling
7
aldesleukin
6
Sorafenib
6
Radiosurgery
6
Immunohistochemistry
6
Hydroxyurea
6
Gefitinib
6
Filgrastim
6
Everolimus
6
Etoposide
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Gliosarcoma
×
Immunotherapy
×
Clear all
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled